AIT Therapeutics Inc Stock OTC Bulletin Board
Stocks
Medical Equipment, Supplies & Distribution
| Market Cap | 4.84M 4.18M 3.84M 3.61M 6.79M 457M 6.85M 45.51M 17.72M 224M 18.17M 17.78M 776M | P/E 2026 * |
-0.1x | P/E 2027 * | -0.21x |
|---|---|---|---|---|---|
| Enterprise Value | 4.84M 4.18M 3.84M 3.61M 6.79M 457M 6.85M 45.51M 17.72M 224M 18.17M 17.78M 776M | EV / Sales 2026 * |
0.6x | EV / Sales 2027 * | 0.38x |
| Free-Float |
96.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: AIT Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Goodman
CEO | Chief Executive Officer | - | 2026-03-26 |
Daniel Moorhead
DFI | Director of Finance/CFO | 53 | 2026-01-04 |
John Jett
CTO | Chief Tech/Sci/R&D Officer | - | 2024-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Erick Lucera
BRD | Director/Board Member | 58 | 2017-08-09 |
Yoori Lee
BRD | Director/Board Member | 54 | 2018-01-01 |
William Forbes
BRD | Director/Board Member | 65 | 2018-08-12 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 4.84M | |
| +0.21% | -0.94% | -32.93% | -16.77% | 154B | |
| +1.16% | -1.72% | -7.91% | -11.23% | 100B | |
| +3.24% | +11.17% | +66.32% | +63.36% | 57.66B | |
| -1.48% | -2.60% | -7.61% | +48.60% | 53.91B | |
| +0.50% | -3.39% | -15.56% | -44.49% | 39.02B | |
| -0.44% | -1.94% | - | - | 30.8B | |
| +2.02% | -3.38% | -10.25% | -44.06% | 27.49B | |
| +0.25% | -1.66% | +49.05% | -11.27% | 22.86B | |
| +0.58% | -0.22% | -14.12% | -3.95% | 20.68B | |
| Average | +0.62% | -0.97% | +3.37% | -2.48% | 56.32B | |
| Weighted average by Cap. | +0.68% | -0.61% | -5.28% | -1.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.08M 6.97M 6.41M 6.03M 11.33M 762M 11.43M 75.93M 29.56M 374M 30.32M 29.67M 1.29B | 12.7M 10.95M 10.07M 9.48M 17.81M 1.2B 17.96M 119M 46.47M 588M 47.66M 46.64M 2.03B |
| Net income | -30.17M -26.03M -23.93M -22.52M -42.33M -2.85B -42.68M -284M -110M -1.4B -113M -111M -4.83B | -29.84M -25.74M -23.66M -22.27M -41.86M -2.82B -42.21M -280M -109M -1.38B -112M -110M -4.78B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
